Evidence map›Paper›PMID 17522712›Full record

ReviewNature reviews. Cancer2007

The cofilin pathway in breast cancer invasion and metastasis.

Weigang Wang, Robert Eddy, John Condeelis

Abstract readReview
In one paragraph

Review in Nature reviews. Cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 246 papers.

0numbers the graph read from it
0cells of the map it votes in
246citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

246 citing papers in PubMed.

  1. Plasma proteomic profiling in dogs with pheochromocytoma.Journal of veterinary internal medicine · 2026
    Article
  2. Observational
  3. Review
  4. Exploring the Therapeutic Potential ofAnti-cancer agents in medicinal chemistry · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

186 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Weigang WangExperimental Therapeutics, ImClone Systems Incorporated, New York, New York, USA.
Robert Eddy
John Condeelis

Funding

Tumor Progression and MetastasisP01CA100324 · NCI · YESHIVA UNIVERSITY · PI CONDEELIS, JOHN S · 2003 to 2018
$30.0M
SIGNAL TRANSDUCTION AND ACTIN DURING AMOEBOID CHEMOTAXISR01GM038511 · NIGMS · YESHIVA UNIVERSITY · PI CONDEELIS, JOHN S · 1988 to 2008
$2.8M
NCI NIH HHS CA100324NCI NIH HHS P01 CA100324NIGMS NIH HHS GM38511NIGMS NIH HHS R01 GM038511
6 · The paper itself

Abstract

Recent evidence indicates that metastatic capacity is an inherent feature of breast tumours and not a rare, late acquired event. This has led to new models of metastasis. The interpretation of expression-profiling data in the context of these new models has identified the cofilin pathway as a major determinant of metastasis. Recent studies indicate that the overall activity of the cofilin pathway, and not that of any single gene within the pathway, determines the invasive and metastatic phenotype of tumour cells. These results predict that inhibitors directed at the output of the cofilin pathway will have therapeutic benefit in combating metastasis.

Indexed as

Neoplasm InvasivenessActin Depolymerizing FactorsAnimalsBreast NeoplasmsCell Line, TumorDrosophila melanogasterEpidermal Growth FactorFemaleHumansModels, BiologicalModels, MolecularMorphogenesisNeoplasm MetastasisSignal TransductionActin Depolymerizing FactorsEpidermal Growth Factor

Identifiers

PMID17522712
PMCPMC4270061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.